Therapy Directory

Fulvestrant clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Fulvestrant as a study intervention. Browse Fulvestrant recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 8:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

294

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Non Small Cell Lung Carcinoma
Interventions: Fulvestrant and Erlotinib; Drug
Lead sponsor: Lyudmila Bazhenova, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Metastatic Breast Cancer
Interventions: Blood collection; Other
Lead sponsor: Janssen Diagnostics, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 18
States / cities: Phoenix, Arizona • Fort Myers, Florida • St. Petersburg, Florida + 14 more

Conditions: Breast Cancer
Interventions: Everolimus, Fulvestrant; Drug
Lead sponsor: Mara Chambers; Other
Eligibility: 45 Years and older · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Estrogen Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions: BKM120, Fulvestrant, biopsy; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Cancer
Interventions: Fulvestrant, GDC-0941, GDC-0941 Matching Placebo, GDC-0980, GDC-0980 Matching Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 41
States / cities: Birmingham, Alabama • Hayward, California • Oakland, California + 35 more

Conditions: Advanced Solid Malignancies, Breast Cancer - ER+, HER2 -, Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation
Interventions: AZD8835, AZD8835 in combination with fulvestrant; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Denver, Colorado • Greenville, South Carolina • Nashville, Tennessee + 2 more

Conditions: Advanced Breast Cancer
Interventions: AZD2171, Fulvestrant; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 6
States / cities: Burbank, California • Los Angeles, California • Palm Springs, California + 3 more

Conditions: Metastatic Breast Cancer
Interventions: Dovitinib, Fulvestrant, Dovitinib Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 18
States / cities: Chandler, Arizona • Fayetteville, Arkansas • Duarte, California + 15 more

Conditions: Breast Cancer
Interventions: fulvestrant; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 24
States / cities: Mobile, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 21 more

Conditions: Advanced Breast Cancer
Interventions: Dasatinib, Fulvestrant; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 28
States / cities: Sedona, Arizona • Tucson, Arizona • Hudson, Florida + 22 more

Conditions: Normal Healthy Volunteers
Interventions: Fulvestrant, Anastrozole, Placebo, Somatostatin; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 55 Years to 80 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Breast Neoplasms
Interventions: CP-751,871, exemestane, Fulvestrant; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 33
States / cities: La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 10 more

About this Fulvestrant clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Fulvestrant as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Fulvestrant.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Fulvestrant clinical trials

Filter and sort this therapy

Live official records

Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer

Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index

Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure

BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy

Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours

AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.

Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer

ICI 182780 in Treating Women With Metastatic Breast Cancer

Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor

Impact of Endogenous E2 on SSI and GH Rebound

Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer

About this Fulvestrant clinical trials directory page